Kirr Marbach & Co. LLC IN trimmed its position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 0.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,008 shares of the medical equipment provider’s stock after selling 435 shares during the period. Zimmer Biomet comprises approximately 2.2% of Kirr Marbach & Co. LLC IN’s portfolio, making the stock its 25th biggest holding. Kirr Marbach & Co. LLC IN’s holdings in Zimmer Biomet were worth $10,124,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in ZBH. Fred Alger Management Inc. raised its holdings in shares of Zimmer Biomet by 48.6% during the second quarter. Fred Alger Management Inc. now owns 1,194,763 shares of the medical equipment provider’s stock worth $133,144,000 after acquiring an additional 390,517 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Zimmer Biomet by 96.7% during the second quarter. Renaissance Technologies LLC now owns 596,000 shares of the medical equipment provider’s stock worth $66,418,000 after acquiring an additional 293,000 shares in the last quarter. State of New Jersey Common Pension Fund D raised its holdings in shares of Zimmer Biomet by 423.0% during the second quarter. State of New Jersey Common Pension Fund D now owns 316,397 shares of the medical equipment provider’s stock worth $35,259,000 after acquiring an additional 255,897 shares in the last quarter. Voya Investment Management LLC raised its holdings in shares of Zimmer Biomet by 246.5% during the second quarter. Voya Investment Management LLC now owns 358,559 shares of the medical equipment provider’s stock worth $39,958,000 after acquiring an additional 255,088 shares in the last quarter. Finally, Cornerstone Wealth Management LLC raised its holdings in shares of Zimmer Biomet by 119.3% during the third quarter. Cornerstone Wealth Management LLC now owns 35,143 shares of the medical equipment provider’s stock worth $299,000 after acquiring an additional 217,146 shares in the last quarter. Institutional investors and hedge funds own 87.22% of the company’s stock.

Several brokerages have recently issued reports on ZBH. Needham & Company LLC raised their price target on Zimmer Biomet from $146.00 to $150.00 and gave the company a “strong-buy” rating in a research report on Monday, July 30th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $150.00 price target on shares of Zimmer Biomet in a research report on Monday, August 27th. Sanford C. Bernstein began coverage on Zimmer Biomet in a research report on Wednesday, June 27th. They issued an “underperform” rating and a $96.00 price target on the stock. Piper Jaffray Companies raised their price target on Zimmer Biomet from $110.00 to $120.00 and gave the company a “neutral” rating in a research report on Monday, July 30th. Finally, BTIG Research began coverage on Zimmer Biomet in a research report on Thursday, August 16th. They issued a “neutral” rating on the stock. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and fifteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $135.33.

ZBH stock traded down $0.21 during trading on Monday, reaching $124.19. 52,318 shares of the stock were exchanged, compared to its average volume of 994,062. Zimmer Biomet Holdings Inc has a twelve month low of $104.28 and a twelve month high of $134.55. The company has a market cap of $25.31 billion, a PE ratio of 15.37, a price-to-earnings-growth ratio of 2.28 and a beta of 1.08. The company has a quick ratio of 1.25, a current ratio of 2.41 and a debt-to-equity ratio of 0.78.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Friday, July 27th. The medical equipment provider reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.04. Zimmer Biomet had a return on equity of 13.53% and a net margin of 21.67%. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.99 billion. During the same period last year, the business earned $2.08 earnings per share. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. On average, equities research analysts anticipate that Zimmer Biomet Holdings Inc will post 7.66 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 31st. Investors of record on Friday, September 28th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date is Thursday, September 27th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 11.96%.

In related news, VP Chad F. Phipps sold 30,100 shares of Zimmer Biomet stock in a transaction dated Friday, September 21st. The stock was sold at an average price of $132.37, for a total transaction of $3,984,337.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Tony W. Collins sold 2,778 shares of the firm’s stock in a transaction dated Tuesday, July 31st. The stock was sold at an average price of $125.77, for a total transaction of $349,389.06. The disclosure for this sale can be found here. 0.71% of the stock is owned by company insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

See Also: Moving Average – How it Helps Investors in Stock Selection

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.